Savara (NASDAQ:SVRA) Sees Unusually-High Trading Volume – Here’s Why

Savara Inc. (NASDAQ:SVRA) shares saw an uptick in trading volume on Wednesday . 993,000 shares were traded during mid-day trading, a decline of 38% from the previous session’s volume of 1,606,575 shares.The stock last traded at $5.77 and had previously closed at $5.84.

Analysts Set New Price Targets

A number of research analysts have issued reports on SVRA shares. Oppenheimer started coverage on shares of Savara in a report on Friday, April 24th. They issued an “outperform” rating and a $11.00 target price on the stock. Wall Street Zen upgraded shares of Savara from a “sell” rating to a “hold” rating in a report on Saturday, June 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Savara currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.14.

Savara Stock Up 1.8%

The firm has a fifty day moving average price of $5.52 and a 200-day moving average price of $5.52. The company has a quick ratio of 13.47, a current ratio of 13.47 and a debt-to-equity ratio of 0.17. The firm has a market cap of $1.18 billion, a price-to-earnings ratio of -10.27 and a beta of 0.24.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). As a group, sell-side analysts forecast that Savara Inc. will post -0.57 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. VR Adviser LLC boosted its position in shares of Savara by 8.4% in the fourth quarter. VR Adviser LLC now owns 13,740,375 shares of the company’s stock worth $82,854,000 after acquiring an additional 1,059,332 shares during the last quarter. Vanguard Group Inc. grew its holdings in Savara by 20.8% in the fourth quarter. Vanguard Group Inc. now owns 10,041,647 shares of the company’s stock valued at $60,551,000 after purchasing an additional 1,728,453 shares during the period. Nantahala Capital Management LLC increased its position in Savara by 5.4% during the third quarter. Nantahala Capital Management LLC now owns 8,775,375 shares of the company’s stock worth $31,328,000 after purchasing an additional 450,000 shares during the last quarter. Polar Capital Holdings Plc acquired a new position in Savara during the fourth quarter worth approximately $50,086,000. Finally, RTW Investments LP acquired a new position in Savara during the fourth quarter worth approximately $35,893,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.